Infectious and noninfectious endophthalmitis after intravitreal bevacizumab

被引：50

作者：

Jonas, Jost B. ^{[1
]}

Spandau, Ulrich H. ^{[1
]}

Rensch, Florian ^{[1
]}

Von Baltz, Stefan ^{[1
]}

Schlichtenbrede, Frank ^{[1
]}

机构：

[1] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, D-68167 Mannheim, Germany

来源：

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | 2007年 / 23卷 / 03期

关键词：

D O I：

10.1089/jop.2006.0146

中图分类号：

R77 [眼科学];

学科分类号：

100212 [眼科学];

摘要：

Aims: The aim of this study was to evaluate the rate of infectious and noninfectious endophthalmitis after an intravitreal injection of bevacizumab. Methods: This clinical interventional case-series study included 1218 intravitreal injections of 1.5 mg of bevacizumab consecutively performed for 684 eyes with exudative age-related macular degeneration. Among the injections were 534 reinjections. Follow-up after each injection was at least 4 weeks. Results: One (1) eye developed an infectious endophthalmitis 3 days after a second injection. In none of the other eyes, were signs of an infectious or noninfectious endophthalmitis observed with the cellular infiltration or amorphous opacification of the vitreous as marked by the Tyndall phenomenon in the anterior chamber, retinal infiltration, or pain. Conclusions: The rate of infectious endophthalmitis after an intravitreal injection of 1.5 mg bevacizumab may be approximately 1:1000, similar to injections of other drugs available thus far.

引用

页码：240 / 242

页数：3

共 7 条

[1]

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].

Avery, RL ;

Pieramici, DJ ;

Rabena, MD ;

Castellarin, AA ;

Nasir, MA ;

Giust, MJ .

OPHTHALMOLOGY, 2006, 113 (03) :363-372

[2]

Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].

Brown, David M. ;

Kaiser, Peter K. ;

Michels, Mark ;

Soubrane, Gisele ;

Heier, Jeffrey S. ;

Kim, Robert Y. ;

Sy, Judy P. ;

Schneider, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444

[3]

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion - A short-term study [J].

Iturralde, Diana ;

Spaide, Richard F. ;

Meyerle, Catherine B. ;

Klancnik, Jay M. ;

Yannuzzi, Lawrence A. ;

Fisher, Yale L. ;

Sorenson, John ;

Slakter, Jason S. ;

Freund, K. Bailey ;

Cooney, Michael ;

Fine, Howard F. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :279-284

[4]

Endophthalmitis after intravitreal injection of triamcinolone acetonide [J].

Jonas, JB ;

Kreissig, I ;

Degenring, RF .

ARCHIVES OF OPHTHALMOLOGY, 2003, 121 (11) :1663-1664

[5]

Acute endophthalmitis following intravitreal triamcinolone acetonide injection [J].

Moshfeghi, DM ;

Kaiser, PK ;

Scott, IU ;

Sears, JE ;

Benz, M ;

Sinesterra, JP ;

Kaiser, RS ;

Bakri, S ;

Maturi, RK ;

Belmont, J ;

Beer, PM ;

Murray, TG ;

Quiroz-Mercado, H ;

Mieler, WF .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (05) :791-796

[6]

Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion [J].

Rosenfeld, PJ ;

Fung, AE ;

Puliafito, CA .

OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :336-339

[7]

Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration [J].

Rosenfeld, PJ ;

Moshfeghi, AA ;

Puliafito, CA .

OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :331-335

← 1 →